Gender Differences in a Mouse Model of Chemotherapy-Induced Neuropathic Pain Publisher Pubmed

Summary: Study finds paclitaxel causes stronger pain in female mice. Why do genders differ in pain response? #NeuropathicPain #CancerTreatment

Najiesfahani H^{1, 2} ; Vaseghi G¹ ; Safaeian L³ ; Pilehvarian AA² ; Abed A⁴ ; Rafieiankopaei M⁵
Source: Laboratory Animals Published:2016

Abstract

Chemotherapy-induced neuropathic pain is one of the major problems for cancer patients. Although paclitaxel and cisplatin are widely used in women, most laboratory studies of chemotherapy-induced neuropathic pain have been conducted on male animals. The current study examined the gender differences in chemotherapyinduced neuropathic pain in mice. Neuropathic pain was induced by intraperitoneal injection of paclitaxel (2 mg/kg) for five consecutive days and cisplatin (1 mg/kg) for seven consecutive days. Cold allodynia was evaluated by measuring the paw withdrawal frequency and duration of paw licking in mice; however, mechanical allodynia was assessed by von Frey filaments. Neuropathic pain began to manifest after a few days (P<0.001). Cold allodynia was more robust in female mice (P<0.001) treated with paclitaxel, while no differences were observed between the two genders in the manifestation of paclitaxel-induced mechanical allodynia. Interestingly, no gender differences were observed in cisplatin-induced cold and mechanical allodynia tests. In conclusion, gender differences play a major role in neuropathic pain induced by paclitaxel. The differences between male and female animals should be considered in future studies and the findings should be generalized to humans with caution. © The Author(s) 2015.